Galectin

Galectin

Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.

Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans.Galectins are typically divided into three groups based on their structural characteristics: (i) prototypical galectins (Galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), which are characterized by asingle CRD and can function as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), which has asingle CRD and a Galectins have recently been linked to important therapeutic factors that affect whether a variety of anticancer treatment modalities, such as chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies are effective or ineffective.

Galectin related products

Structure Cat No. Product Name CAS No. Product Description
V83485 6Lac[6]Met 1132892-04-6
V74909 DB21, Galectin-1 Antagonist 1623027-80-4 DB21, Galectin-1 Antagonist is a dibenzofuran-conjugated peptide mimetic that works as an allosteric inhibitor of galectin-1 (GAL1) binding to cell surface glycans.
V76994 G3-C12 TFA G3-C12 (TFA) is a galectin-3 binding peptide with Kd of 88 nM and has anti-tumor activity.
V74910 Galectin-3 antagonist 1 2921603-03-2 Galectin-3 antagonist 1 (compound 15) is a potent and specific Galectin-3 (Gal-3) antagonist (inhibitor) with a Kd of 5.3 μM.
V74911 Galectin-3 antagonist 2 2921603-02-1 Galectin-3 is a β-galactoside-specific carbohydrate recognition protein (lectin) that has the ability to promote the migration of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and withstand drug treatment.
V74912 Galectin-3-IN-2 2883648-71-1 Galectin-3-IN-2 (Compound 9) is a potent multivalent galectin-3 (Gal-3; IC50=8.3 μM) inhibitor.
V79555 Galectin-3/galectin-8-IN-1 Galectin-3/galectin-8-IN-1 (Compound 53) is a dual galectin-3 and galectin-8 C-terminal domain inhibitor (antagonist) with K d values of 4.12 μM and 6.04 μM, respectively.
V79556 Galectin-3/galectin-8-IN-2 Galectin-3/galectin-8-IN-2 (Compound 57) is a dual galectin-3 and galectin-8 C-terminal domain inhibitor (antagonist) with Kds of 12.8 μM and 2.06 μM, respectively.
V80258 Galectin-8-IN-1 Galectin-8-IN-1 is a selective ligand of galectin-8N, with a Kd of 48 μM.
V83388 Galectin-8-IN-2 1044566-24-6
V74913 Galectin-8N-IN-1 2667628-25-1 Galectin-8N-IN-1 (compound 19a) is a potent and specific galectin-8N inhibitor (antagonist) with a Kd of 1.8 μM.
V21523 GB1107 1978336-61-6 GB1107 (GB-1107) is a novel, potent, selective, orally bioavailable galectin-3 (GAL-3) inhibitor with anticancer activity.
V85894 GB1490 2172866-22-5
V15975 TD-139 1450824-22-2 TD-139 is a novel and potent galectin-3 inhibitor with the potential for the treatment of idiopathic pulmonary fibrosis (IPF)
V74907 Thiodigalactoside (TDG) 51555-87-4 Thiodigalactoside (TDG) is an orally bioactive and potent galectin (GAL) inhibitor (antagonist) with Kds of 24 μM and 49 μM for GAL-1 and GAL-3, respectively.
Contact Us Back to top